Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HK1 | P19367 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631687 | 0.83 | ADORA2A (0.45) | MAPTALDH1A1HPGDADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL27631852 | 0.82 | ADORA2A (0.44) | MAPTALDH1A1HPGDADORA2AADORA1 | |
| SCHEMBL1116418 | 0.81 | PIK3CG (0.60) | HRH3ADORA2AADORA1ADORA2BIKBKB | |
| SCHEMBL4418415 | 0.81 | ADORA2A (0.59) | ADORA2AADORA1ADORA2B | |
| SCHEMBL19932545 | 0.81 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BPIK3CGPIK3CD | |
| SCHEMBL4411196 | 0.81 | RAB9A (0.56) | RAB9AALDH1A1ADORA2AADORA1ADORA2B | |
| SCHEMBL27612323 | 0.79 | CSNK1A1 (0.55) | ALDH1A1HPGDADORA2AADORA1ADORA2B | |
| SCHEMBL5175214 | 0.79 | KDR (0.47) | MAPTRAB9AKDM4ESMN1; SMN2EGFR | |
| SCHEMBL27631918 | 0.78 | PIK3CG (0.64) | HRH2HRH3MAPTHPGDADORA2A | |
| SCHEMBL27716588 | 0.78 | CSNK1A1 (0.53) | ALDH1A1HPGDADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550460-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7435814-B2 | 2,4-Pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7332484-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7329671-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329672-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20060135543-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | MIDCAP FINANCIAL TRUST | 2006-03-16 | — | — | US | disclosed |
| US-20060035916-A1 | N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | disclosed |
| US-20060025410-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | MIDCAP FINANCIAL TRUST | 2006-02-02 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | FCER2, FCGR1A, HRH4 | HRH2 5/4885HRH3 21/4885MAPT 4177/4885 |
| US-20060035916-A1 | N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | HRH2 8/4885HRH3 9/4885MAPT 2955/4885 |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | FCER2, FCGR1A, FCGR2A | HRH2 19/4885HRH3 23/4885MAPT 4372/4885 |
| US-20060025410-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | HRH2 35/4885HRH3 71/4885MAPT 3401/4885 |
| US-20060135543-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | HRH2 35/4885HRH3 71/4885MAPT 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.